South Dakota Patent of the Month – April 2024

ImmutriX Therapeutics, Inc., a medical technology company in Rapid City, South Dakota, is developing a new way to cleanse whole blood to sequester toxic or undesired molecules from the circulatory system. In line with this effort, the company has been granted a patent for their therapeutic compositions designed to target viral infections.

ImmutriX Therapeutics’ method involves a multi-step process that starts with obtaining bodily fluid from the subject containing disease mediators. This fluid is then treated with an adsorbent material comprising synthetic carbon particles (SCPs), leading to the production of filtrates. These filtrates undergo further purification through contact with adsorbent materials containing SCPs and either anion or cation exchange resins, depending on the specific ratios required. Finally, the purified filtrate is administered back to the subject, effectively reducing the level of disease mediators.

Key to the effectiveness of this method is the use of SCPs and exchange resins, which have been shown to efficiently adsorb disease mediators from bodily fluids. Additionally, the incorporation of sanitization steps and compatibilizers ensures the safety and compatibility of the materials used in the process.

ImmutriX Therapeutics’ extracorporeal system further enhances the treatment process, providing a robust platform for the removal of disease mediators from the subject’s blood. With at least three adsorbent materials and advanced monitoring capabilities, this system offers a comprehensive solution for treating subjects infected with SARS-CoV-2 and other viral-associated diseases.

The significance of Immutrix’s invention extends beyond the COVID-19 pandemic, offering hope for the treatment of other viral infections causing immunosuppression. By targeting the underlying mechanisms of viral-induced immune dysregulation, this method represents a promising avenue for improving patient outcomes and reducing the burden of viral diseases on global healthcare systems.

Are you developing new technology for an existing application? Did you know your development work could be eligible for the R&D Tax Credit and you can receive up to 14% back on your expenses? Even if your development isn’t successful your work may still qualify for R&D credits (i.e. you don’t need to have a patent to qualify). To find out more, please contact a Swanson Reed R&D Specialist today or check out our free online eligibility test.

Who We Are:

Swanson Reed is one of the U.S.’ largest Specialist R&D tax advisory firms. We manage all facets of the R&D tax credit program, from claim preparation and audit compliance to claim disputes.

Swanson Reed regularly hosts free webinars and provides free IRS CE and CPE credits for CPAs. For more information please visit us at or contact your usual Swanson Reed representative.

Recent Posts